Taiyen Biotech Operating Margin vs. Gross Profit

1737 Stock  TWD 32.30  0.05  0.15%   
Considering the key profitability indicators obtained from Taiyen Biotech's historical financial statements, Taiyen Biotech Co may not be well positioned to generate adequate gross income at the moment. It has a very high risk of underperforming in January. Profitability indicators assess Taiyen Biotech's ability to earn profits and add value for shareholders.
For Taiyen Biotech profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Taiyen Biotech to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Taiyen Biotech Co utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Taiyen Biotech's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Taiyen Biotech Co over time as well as its relative position and ranking within its peers.
  
Check out Trending Equities.
Please note, there is a significant difference between Taiyen Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Taiyen Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Taiyen Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Taiyen Biotech Gross Profit vs. Operating Margin Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Taiyen Biotech's current stock value. Our valuation model uses many indicators to compare Taiyen Biotech value to that of its competitors to determine the firm's financial worth.
Taiyen Biotech Co is rated second in operating margin category among its peers. It is rated fifth in gross profit category among its peers fabricating about  11,727,036,721  of Gross Profit per Operating Margin. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Taiyen Biotech's earnings, one of the primary drivers of an investment's value.

Taiyen Gross Profit vs. Operating Margin

Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.

Taiyen Biotech

Operating Margin

 = 

Operating Income

Revenue

X

100

 = 
0.12 %
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.
Gross Profit is the most basic measure of business operational efficiency. It is simply the difference between sales revenue and the cost associated with making a product or providing a service. It is calculated before deducting administrative expenses, taxes, and interest payments.

Taiyen Biotech

Gross Profit

 = 

Revenue

-

Cost of Revenue

 = 
1.37 B
Gross Profit varies significantly from one sector to another and tells an investor how much money a business would have made if it didn't have to pay any overhead expenses such as salary, taxes, or rent.

Taiyen Gross Profit Comparison

Taiyen Biotech is currently under evaluation in gross profit category among its peers.

Taiyen Biotech Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Taiyen Biotech, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Taiyen Biotech will eventually generate negative long term returns. The profitability progress is the general direction of Taiyen Biotech's change in net profit over the period of time. It can combine multiple indicators of Taiyen Biotech, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Taiyen Biotech Co., Ltd. provides various health and beauty products under the TAIYEN brand Hong Kong, Taiwan, Mainland China, and Macau. The company was founded in 1952 and is based in Tainan, Taiwan. TAIYEN BIOTECH is traded on Taiwan Stock Exchange in Taiwan.

Taiyen Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Taiyen Biotech. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Taiyen Biotech position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Taiyen Biotech's important profitability drivers and their relationship over time.

Use Taiyen Biotech in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Taiyen Biotech position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Taiyen Biotech will appreciate offsetting losses from the drop in the long position's value.

Taiyen Biotech Pair Trading

Taiyen Biotech Co Pair Trading Analysis

The ability to find closely correlated positions to Taiyen Biotech could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Taiyen Biotech when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Taiyen Biotech - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Taiyen Biotech Co to buy it.
The correlation of Taiyen Biotech is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Taiyen Biotech moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Taiyen Biotech moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Taiyen Biotech can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Taiyen Biotech position

In addition to having Taiyen Biotech in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Recreation Thematic Idea Now

Recreation
Recreation Theme
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Recreation theme has 34 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Recreation Theme or any other thematic opportunities.
View All  Next Launch

Additional Tools for Taiyen Stock Analysis

When running Taiyen Biotech's price analysis, check to measure Taiyen Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Taiyen Biotech is operating at the current time. Most of Taiyen Biotech's value examination focuses on studying past and present price action to predict the probability of Taiyen Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Taiyen Biotech's price. Additionally, you may evaluate how the addition of Taiyen Biotech to your portfolios can decrease your overall portfolio volatility.